Bolt Biotherapeutics, Inc. – NASDAQ:BOLT
Bolt Biotherapeutics stock price today
$4.85
+4.33
+836.29%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Bolt Biotherapeutics stock price monthly change
-30.87%
month
Bolt Biotherapeutics stock price quarterly change
-30.87%
quarter
Bolt Biotherapeutics stock price yearly change
-50.19%
year
Bolt Biotherapeutics key metrics
Market Cap | 18.37M |
Enterprise value | 65.56M |
P/E | -0.54 |
EV/Sales | 11.44 |
EV/EBITDA | -0.76 |
Price/Sales | 9.11 |
Price/Book | 0.30 |
PEG ratio | -0.02 |
EPS | -1.66 |
Revenue | 11.32M |
EBITDA | -73.46M |
Income | -63.02M |
Revenue Q/Q | 188.82% |
Revenue Y/Y | 67.96% |
Profit margin | -1537.76% |
Oper. margin | -1576.56% |
Gross margin | 48.94% |
EBIT margin | -1576.56% |
EBITDA margin | -648.71% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBolt Biotherapeutics stock price history
Bolt Biotherapeutics stock forecast
Bolt Biotherapeutics financial statements
| Jun 2023 | 1.43M | -18.05M | -1260.08% |
|---|---|---|---|
| Sep 2023 | 2.52M | -16.25M | -643.08% |
| Dec 2023 | 2.08M | -17.90M | -857.01% |
| Mar 2024 | 5.27M | -10.81M | -204.99% |
| Dec 2023 | 2.08M | -17.90M | -857.01% |
|---|---|---|---|
| Mar 2024 | 5.27M | -10.81M | -204.99% |
| Oct 2025 | 750K | -11.42M | -1522.74% |
| Dec 2025 | 750K | -11.80M | -1573.49% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 190696000 | 48.56M | 25.47% |
|---|---|---|---|
| Sep 2023 | 175355000 | 47.09M | 26.86% |
| Dec 2023 | 159784000 | 47.04M | 29.44% |
| Mar 2024 | 142892000 | 38.73M | 27.11% |
| Jun 2023 | -15.11M | 13.58M | 147K |
|---|---|---|---|
| Sep 2023 | -16.74M | 12.65M | 0 |
| Dec 2023 | -14.26M | 15.80M | 106K |
| Mar 2024 | -16.75M | 10.20M | 0 |
Bolt Biotherapeutics alternative data
| Aug 2023 | 94 |
|---|---|
| Sep 2023 | 94 |
| Oct 2023 | 94 |
| Nov 2023 | 94 |
| Dec 2023 | 94 |
| Jan 2024 | 94 |
| Feb 2024 | 94 |
| Mar 2024 | 100 |
| Apr 2024 | 100 |
| May 2024 | 100 |
| Jun 2024 | 100 |
| Jul 2024 | 100 |
Bolt Biotherapeutics other data
71.67%
-0.68%
of BOLT is owned by hedge funds
26.72M
-132.45K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 289454 |
| Dec 2023 | 10000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | QUINN WILLIAM P. officer: Chief Fi.. | Common Stock | 7,500 | $0.95 | $7,125 | ||
Purchase | QUINN WILLIAM P. officer: Chief Fi.. | Common Stock | 2,500 | $0.78 | $1,955 | ||
Sale | ENGLEMAN EDGAR director | Common Stock | 108,145 | $0.86 | $92,788 | ||
Sale | ENGLEMAN EDGAR director | Common Stock | 14,934 | $0.86 | $12,813 | ||
Sale | ENGLEMAN EDGAR director | Common Stock | 22,674 | $0.91 | $20,543 | ||
Sale | ENGLEMAN EDGAR director | Common Stock | 3,131 | $0.91 | $2,837 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 1,707 | $0.9 | $1,536 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 236 | $0.9 | $212 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 1,457 | $0.9 | $1,311 | ||
Sale | ENGLEMAN EDGAR director | Common Stock | 1,707 | $0.9 | $1,538 |
| Quarter | Transcript |
|---|---|
| Q1 2024 17 May 2024 | Q1 2024 Earnings Call Transcript |
-
What's the price of Bolt Biotherapeutics stock today?
One share of Bolt Biotherapeutics stock can currently be purchased for approximately $4.85.
-
When is Bolt Biotherapeutics's next earnings date?
Unfortunately, Bolt Biotherapeutics's (BOLT) next earnings date is currently unknown.
-
Does Bolt Biotherapeutics pay dividends?
No, Bolt Biotherapeutics does not pay dividends.
-
How much money does Bolt Biotherapeutics make?
Bolt Biotherapeutics has a market capitalization of 18.37M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 37.48% to 7.88M US dollars.
-
What is Bolt Biotherapeutics's stock symbol?
Bolt Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "BOLT".
-
What is Bolt Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Bolt Biotherapeutics?
Shares of Bolt Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bolt Biotherapeutics's key executives?
Bolt Biotherapeutics's management team includes the following people:
- Dr. Randall C. Schatzman Chief Executive Officer & Director(age: 70, pay: $706,050)
- Dr. Edith A. Perez M.D. Chief Medical Officer(age: 68, pay: $607,490)
- Mr. William P. Quinn Chief Financial Officer(age: 54, pay: $454,690)
- Mr. Grant Yonehiro Chief Bus. Officer(age: 61, pay: $434,070)
- Dr. David Dornan Ph.D. Chief Scientific Officer(age: 47, pay: $422,500)
-
How many employees does Bolt Biotherapeutics have?
As Jul 2024, Bolt Biotherapeutics employs 100 workers.
-
When Bolt Biotherapeutics went public?
Bolt Biotherapeutics, Inc. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
-
What is Bolt Biotherapeutics's official website?
The official website for Bolt Biotherapeutics is boltbio.com.
-
Where are Bolt Biotherapeutics's headquarters?
Bolt Biotherapeutics is headquartered at 900 Chesapeake Drive, Redwood City, CA.
-
How can i contact Bolt Biotherapeutics?
Bolt Biotherapeutics's mailing address is 900 Chesapeake Drive, Redwood City, CA and company can be reached via phone at +65 06659295.
Bolt Biotherapeutics company profile:
Bolt Biotherapeutics, Inc.
boltbio.comExchange:
NASDAQ
Full time employees:
100
Industry:
Biotechnology
Sector:
Healthcare
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
900 Chesapeake Drive
Redwood City, CA 94063
Redwood City, CA 94063
CIK: 0001641281
ISIN: US0977021049
CUSIP: 097702104
